Upstate Active Clinical Trials
Study Title:Celgene Protocol CC-5013-CLL-002: A Phase 3, Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The CONTINUUM Trial)
Upstate Institutional Review Board (IRB) Number:230326
Patient Age Group:Adults
Principal Investigator:Bernard J Poiesz, MD
Who can I contact for more information?
Name: Patricia M Benz